StockNews.com Initiates Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

Research analysts at StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report released on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Performance

Shares of TCON opened at $0.03 on Thursday. The company has a market cap of $102,300.00, a price-to-earnings ratio of 0.01 and a beta of 1.43. The stock has a fifty day moving average price of $0.08 and a two-hundred day moving average price of $0.56. TRACON Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $14.75.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.